Our real-world patient data showed the cost and QoL burden of HAE treatment with on-demand‐only therapy.
Novel subcutaneous (SC) prophylactic therapies are transforming the treatment landscape of hereditary angioedema (HAE). Although questions are being raised about their cost, little attention has been paid to the cost and quality of life (QoL) impact of using on-demand‐only medications.
We assessed the overall economic burden of on-demand‐only treatment for HAE and compared patient QoL with patients who received novel SC prophylactic therapies.
The main conclusions of our study are:
The study is commissioned by the US Hereditary Angioedema Association (HAEA)Download